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Abstract
Background: Most screening programs for sickle cell
disease (SCD) utilize isoelectric focusing (IEF) or high
performance liquid chromatography (HPLC) to detect
haemoglobin (Hb) variants. The first method is not
automated and becomes too tedious when many
samples have to be investigated. The aim of this work
is to explore the capacity of an automated capillary
electrophoresis (CE) system, with full traceability, as
a tool for newborn screening of SCD.
Methods: The Capillarys neonat fast automated
system has been developed by Sebia for newborn
screening. We performed separate studies using dif-
ferent types of samples to evaluate the utility
of the Capillarys for (i) separating Hb S and other
variants, and (ii) for performing the routine activity
of our laboratory for 20 working days.
Results: A throughput of 48 samples per hour with a
loading capacity of 192 samples was achieved. Migra-
tion times of the major Hb variants were distinct.
There were few variants showing similar migration
times to Hb S and Hb C and thalassaemia could be
detected. In addition, late screening, screening of pre-
mature or transfused babies and screening performed
using poor quality Guthrie’s cards did not interfere
with reporting of accurate phenotypes.
Conclusions: Sebia Capillarys neonat fast automated
system is a reliable tool for haemoglobinopathy neo-
natal screening.
Clin Chem Lab Med 2009;47:1423–32.
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ing; sickle cell disease; thalassaemia.
Introduction
The sickling of red cells may result from inheritance
of the gene for sickle haemoglobin (HbS) associated
to another inherited gene for either HbS, or an inter-
action with another haemoglobin (Hb) such as HbC,
*Corresponding author: Jean-Marc Périni, Laboratoire de
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HbD-Punjab, HbE, HbO-Arab, HbLepore, HbG-Phila-
delphia or with b-thalassaemia (1). The strategy
developed in France for newborn screening for sickle
cell disease (SCD) is a combination of two methods
(2): first, isoelectric focusing (IEF) used for primary
screening is rapid but not-automated; second, a sec-
ond tier test incorporates high performance liquid
chromatography (HPLC) with a cation exchange col-
umn. The latter is automated, fast and quantitative.
The first step can become very tedious and time-
consuming when many samples need to be evaluated
(100,000 newborns are tested each year in our screen-
ing laboratory). A technical improvement is necessary
for screening centres with high testing volumes. The
aim of this work is to explore the utility of capillary
electrophoresis (CE) as a powerful tool for SCD new-
born screening. The analytical challenge of this work
is the ability to detect all the haemoglobinopathies
able to induce a sickling of red cells, as well as other
variants of interest such as HbBart’s (a-thalassaemia
marker), whatever the condition of the blood sample.
Two previous studies published by Gulbis et al. (3)
and by Louahabi et al. (4) reported that ‘‘capillary
electrophoresis, due to its high analytical efficiency,
can replace conventional techniques’’ for detecting
haemoglobinopathies. These studies used dried
blood samples from Guthrie cards with normal and
abnormal Hbs that were tested using the new
Capillarys neonat fast technology. They offer the first
prospective evaluation of the Sebia Capillarys
neonat fast automated electrophoresis system applied
to SCD newborn screening. Its performance was com-
pared to well established methods (IEF/HPLC).
Our laboratory, located at the University Hospital of
Lille (France), is one of four accredited French Centres
for SCD neonatal screening. Two-thirds of newborns
in France (Paris region and Southern area excluded)
are analysed by our centre. In addition, SCD screen-
ing for French Guiana, Reunion Island and Mayetta
Island newborns is also performed by our laboratory.
Consequently, in our study not all dried blood sam-
ples were of high quality. Guthrie cards for routine
screening activity of our laboratory were investigated.
Some came from remote regions such as French Gui-
ana. These samples might be several weeks or
months old and kept for 2–3 weeks in a tropical
atmosphere before they were sent to our laboratory.
Thus, the Capillarys neonat fast automated system
was tested under extremely difficult conditions.
Materials and methods
Materials
The automated electrophoresis system Capillarys 2 (Sebia,
Evry, France) was modified in order to improve its loading
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Figure 1 Materials supplied by Sebia (Evry, France) with the Capillarys neonatal fast electrophoresis apparatus.
Segment holders (A); segments identified with barcode (B); humidity chamber (C). Segments and segment holder assembly
can be viewed in (D). Guides located on each side of the segments are useful for maintaining them correctly on the holder.
capacity and analysis throughput. Specific accessories are
described in Figure 1.
Capillary electrophoresis
The pre-analytical step Demineralised water was added
with a multipipette into the wells of the Capillarys segment
for pre-elution of Hb; 3.8 mm spots from the Guthrie cards
were obtained using a BSD Duet puncher (BSD Robotics,
Queensland, Australia). They fell directly into the wells of the
Capillarys segment. The holder moves on an x and y axis
according to the thread between the wells from a segment
and the thread between the segments present on the holder.
The barcode for each sample and the Guthrie card barcode
for each dilution segment are scanned using two specific
barcode readers. A pre-elution time from 2 h up to 3 days at
2–88C in a humidity chamber, without shaking, was applied.
To prepare the racks, a segment is set on a rack, and a tube
containing haemolysing solution is inserted. Racks can be
introduced successively and continuously.
The analytical step (inside Capillarys neonat fast auto-
mated system)
• Automated reading of segment and rack barcodes
• Automated addition of haemolysing solution to the pre-
eluted blood spot samples
• Automated mixing in the wells
• Automated injection without any manual transfer of the
haemolysates into the capillaries
• Eight parallel capillaries are used to analyse the samples
at 10,000 V for 7 min at a temperature of 348C with an
alkaline buffer (pH 9.4)
• Direct measurement of Hb at 415 nm
• Curves are automatically displayed on the screen and
identified by the sample barcode
A throughput of 48 samples per hour was achieved. Up to
24 sample racks (192 samples) can be introduced at one
time.
The post-analytical step The different migration zones of
Hb variants (termed N1–N13) were indicated on the electro-
phoreticgrams. Passing the cursor over a particular zone dis-
plays icon information containing the possible Hb variants
that might be seen in this zone. Abnormal curves (in red) are
automatically discriminated from normal curves (in blue).
Sample collections
Five hundred and sixty-four Guthrie cards with residual dried
blood spots were sequentially selected by our laboratory.
The corresponding heel prick samples were collected
between 3 and 5 days after birth onto Waters grade 903 filter
paper. Birth weight and gestational age were recorded for
each newborn. Four hundred and eighty-five of these new-
borns had a relatively common abnormal Hb. The other sam-
ples were considered to be normal. One hundred and six
premature newborns with normal or abnormal Hb were
included in this cohort of 564 samples. This first sample
collection was investigated retrospectively in Sebia’s labo-
ratories which performed a repeat analysis after the screen-
ing laboratory in Lille (France) had performed its analysis.
The delay between the analysis by IEF/HPLC and the analysis
by the Capillarys neonat fast automated system was three
weeks in the majority of cases, but never exceeded three
months. During this time, the samples were kept at q48C.
Samples from newborns from French Guiana, Reunion
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Island and Mayetta Island were excluded from this part of
the study. Comparison between the two screening strategies
was performed in blinded fashion.
In the second part of this study, we compared the Capil-
larys neonat fast automated system to the established tech-
nique of IEF. All cards received each working day during 4
weeks were tested in parallel with both methods in our
screening laboratory, and using the same staff. IEF was
performed first followed by CE the next day. This second
sample collection contained more normal Guthrie cards
compared with cards obtained with the first collection. This
was used to evaluate the possible integration of the Capil-
larys system into routine newborn screening for SCD.
These samples originated either from metropolitan France
(4307), Reunion Island (957), French Guiana (291) or Mayetta
Island (647).
All samples were collected with consent from the parents.
Method reliability
Different neonatal samples were chosen: samples A and
Bsnormal samples; samples C and Dspathologic samples
(with HbA and HbS); sample Esa series of eight samples (4
normal, 3 HbS heterozygotes, 1 HbBart’s).
Within-run reproducibility Each sample from A to D was
analysed eight times the same day and by the same
technician.
Between-run and between-lot reproducibility Three runs
with the series of sample E were performed with one lot of
buffer and haemolysing solution. This study was completed
using 2=3 runs with two additional lots of buffer and hae-
molysing solution.
No ethical approval was required since the Capillarys has
been evaluated using residual dried blood and this auto-
mated system has been used exclusively to perform screen-
ing for SCD. In France, all samples for newborn screening
are collected with consent of the parents.
Results
The two tier procedure (IEF/HPLC) used as the refer-
ence method for screening of SCD in our study pro-
vides putative identification of clinically significant
haemoglobinopathies and the risk of errors is reduced
(2). Genotyping should be performed following the
first consultation with a paediatrician in order to
establish a definitive diagnosis.
Retrospective analysis of the first cohort
Normal and abnormal patterns The newborn shown
in Figure 2A is normal, while the newborns shown in
Figure 2B and C show patterns frequently observed
in newborn screening: Figure 2B shows the profile of
a newborn that received a blood transfusion and Fig-
ure 2C shows the profile of a very low birth weight
preterm infant. Normal Hbs HbA and HbF (zones N10
and N7, respectively) were clearly identified in normal
newborns (Figure 2A). HbA2 (zone N2) was clearly
distinguishable in the profile from the baby that had
been transfused (Figure 2B). Only in extremely pre-
term infants was the amount of HbA too low to form
a sharp peak (Figure 2C). A premature baby (Figure
2C) can nevertheless be differentiated from a new-
born presenting with b8-thalassaemia: in the absence
of HbA (Figure 2D), a small round peak corresponding
to acetylated HbF was located exclusively in zone N9,
and no HbA peak can be seen in N10; when a small
amount of HbA was mixed with acetylated HbF (sim-
ilar to premature newborn in Figure 2C), the resulting
large round peak was present and borderline between
zones N9 and N10 (i.e., detection of peaks in N9 and
N10).
This cohort included 28 newborns of normal weight
()2500 g) and a term )37 weeks. Some profiles from
normal newborns deviated from the expected normal
pattern. A large peak in N10 (HbA) was observed in
two cases where preterm infants had been trans-
fused. A minor HbA peak in N10 or a large round peak
located between N9 and N10 was seen in 52 cases
from non-transfused preterm babies.
Newborns with HbS variant In Figure 3A, a HbS
peak observed in N4 was associated with a small
round peak in N9 and no peak in N10. This indicated
a F/S homozygous profile. The Capillarys system
was sensitive enough to detect SCD in a 34-week pre-
term newborn (Figure 3B). In Figure 3C, there is no
HbA in N10, a peak of acetylated HbF in N9, and the
presence of HbS and HbC (respectively in N4 and N1).
This indicated a F/SC compound heterozygous profile.
These three newborns with abnormal profile were
identified easily and not confused with a HbS carrier
(Figure 3D).
Among samples obtained in the first collection,
there were 47 newborns with SCD. Forty were FS
homozygotes and seven were F/SC compound hetero-
zygotes, two of which were preterm infants. There
were 307 term newborns and 37 preterm infants
showing a F/AS heterozygous profile. The concentra-
tion of HbS measured by HPLC in premature new-
borns who were homozygous or heterozygous varied
from 0.8% to 4.2%. All were interpreted correctly
according to Capillarys profiles.
Newborns with HbC, D-Punjab or E variants Figures
4 and 5 were interpreted according to the same
scheme: (i) a homozygous profile showing the char-
acteristic variant peak (HbC in N1, Figure 4A; HbD-
Punjab in N5, Figure 5A; HbE in N3, Figure 5C), and
no peak in N10 in the absence of HbA. (ii) A hetero-
zygous profile (Figures 4B, 5B and D) with a charac-
teristic variant peak and a sharp peak in N10
indicating the presence of HbA. (iii) A profile from a
preterm newborn (Figures 4C and 5E) with a small
variant peak and a round peak that borders N9 and
N10, indicating the presence of HbA in small
amounts. No F/AD premature newborns were found
in this cohort.
Among the 564 selected samples, the two new-
borns showing a F/C homozygous profile were iden-
tified correctly. The numbers of HbC, HbD-Punjab or
HbE carriers were 53 (including 8 preterm infants), 12
and 19 (including one premature baby), respectively.
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Figure 2 Newborns without haemoglobin variants.
(A) Normal newborn: 39 w. term; 3445 g. (B) Transfused newborn: 38 w. term; 3100 g. (C) Premature newborn: 30 w. term;
1060 g. (D) Term newborn with b8-thalassaemia.
Newborns with less common b-chain variants
HbKorle-Bu and HbO-Arab variants were selected
because they may have an impact on the specificity
of SCD screening. These two variants migrated in N5
and N2, respectively (Figure 6A and B).
Two newborns with F/AKorle-Bu, 5 with F/AO-Arab
and 1 F/O-Arab homozygote were also included in this
cohort. Electrophoreticgrams showed good agree-
ment with IEF/HPLC.
Newborns with g- and a-chains variants Three pro-
files were observed most frequently: (i) a single peak
detected in N3, higher than HbA (Figure 6C). On the
corresponding HPLC profile, one major peak migrated
between HbF and HbA. This fraction usually corre-
sponded to HbF-Ouled Rabah; (ii) two abnormal peaks
were detected. A major peak and a minor peak locat-
ed in N3 and N5, respectively. The intensity of the first
one was higher than HbA (Figure 6D). Using HPLC, a
minor peak with the same retention time (RT) as HbD-
Punjab was observed, in addition to a major peak
between HbF and HbA. This profile suggests the pres-
ence of HbG-Philadelphia and is in agreement with
IEF; (iii) similar to the second pattern but with peaks
in N11 and N12 (Figure 6E). These eluted using HPLC
as two peaks, weakly retained by the column, and
were considered to be ‘‘fast-moving’’ foetal Hb
variants.
All 23 putative variants of g-/a-chains present in our
cohort were detected by the Capillarys neonat fast
automated system.
Newborns with a-thalassaemia Newborn screening
for SCD allows the opportunity to detect Hb H dis-
ease. Twenty-one newborns, including six preterm
infants, presented with a minor HbBart’s peak migrat-
ing in N13 (Figure 7A), corresponding to single or
double a-chain deletion. Two cases of HbH disease
(triple deletion of a-chain) presented with a marked
peak in N13 (Figure 7B).
Newborns with b-thalassaemia The Capillarys pro-
files from four babies showed only a small round
peak in N9, indicating the absence of HbA and a risk
of b8-thalassaemia. These results were in agreement
with IEF/HPLC. In two other cases, a large round peak
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Figure 3 Newborns with haemoglobin S.
(A) F/S homozygote: 37 w. term; 3490 g. (B) Premature F/S homozygote: 34 w. term; 1300 g; quantification of HbS by Variant
I from Bio-Rad (Bio-Rad Laboratories, Hercules, CA, USA) has given a relative concentration of 1.2%. (C) F/SC compound
heterozygote: 40 w. term; 3900 g. (D) F/AS single heterozygote: 39 w. term; 3180 g.
was present that was borderline between N9 and N10,
and was associated with an HbS variant in N4. This
type of profile was consistent with HbS/bq-thalassae-
mia (Figure 7C).
Prospective analysis of the second cohort
SCD screening with the Capillarys neonate fast
automated system and the BSD Duet Puncher One
Capillarys neonat fast automated system and one
BSD Duet Puncher were provided by Sebia for 20
working days. We analysed 6202 Guthrie cards. To
achieve the throughput of 350 samples per day, the
less fresh Guthrie cards were punched and pre-eluted
overnight. The next morning, 24 racks with the pre-
eluted samples were loaded into the CE apparatus.
Analyses were completed 4 h later. Three hours prior
to the second loading, and in order to let enough time
for punching and pre-elution, 24 new segments were
prepared.
To utilize the Capillarys neonat fast automated
system at full capacity of 576 samples per day, a sup-
plementary cycle of punching and pre-elution of
blood spots (24 segments) needed to be planned dur-
ing the analysis time of the second series for over-
night analyses.
Efficiency of automatic discrimination of normal and
abnormal profiles A profile was considered normal
when HbF and HbA peaks were present. A profile was
considered abnormal and displayed as a red curve
when the following criteria were met: (i) the absor-
bance of HbF peak was very low woptical density (OD)
-0.0018 in N7x. In these cases, the migration zones
are not indicated on the profiles; (ii) no peak was
distinguished in N10, which implied no HbA; (iii)
additional peaks were present in other zones.
Their detection was due to an OD higher than a thresh-
old defined for each zone when compared to the
background.
Among the 6202 samples tested in the second
cohort, 549 profiles (9%) were automatically classified
by the Capillarys using a red colour. In practice, this
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Figure 4 Newborns with haemoglobin C.
(A) F/C homozygote: 39 w. term; 3490 g. (B) F/AC heterozygote: 40 w. term; 3035 g. (C) Premature F/AC heterozygote: 30 w.
term; 2330 g; HbA (HPLC)s1.5%; HbC (HPLC)s1.2%.
labelling of abnormal profiles was activated in four
scenarios:
i. The presence of a distinct HbA2 peak in N2 asso-
ciated with an increase in the amount of HbA. We
found 118 samples with this profile in this cohort.
Twenty were found in newborns screened outside
the usual prescribed time. The intensity of the
HbA peak was equal to HbF (4 cases) or higher (2
cases). It is interesting to note that some pitfalls
can occur when screening is delayed (2–3 months
after birth). The migration zones were not indicat-
ed, despite migration of HbA and HbF at appro-
priate time (10 cases), or HbA/HbF were incorrect-
ly identified as HbF/HbS (4 cases). In one extreme
situation where the infant was tested when nine
months of age, a major peak observed in N7 was
confused with HbF.
For 93 full-term newborns, the HbA peak was as
large as the HbF peak, or even greater, although
these newborns were tested 3–5 days after birth.
This type of profile could be the consequence of
early switching from HbF to HbA (5). A low level
of HbF at birth, as observed in g-thalassaemia
syndromes (6), could also explain this type of pro-
file. Since full-scale display was always applied to
HbF, the size of the HbA and HbA2 peaks conse-
quently appeared increased.
The last five cases corresponded to newborns
that had been transfused as documented in the
medical record. These newborns showed high
amounts of HbA and very low amounts of HbF.
ii. The absence of HbA. In some cases, HbA could
not be detected by the Capillarys. The best illus-
tration of this problem is illustrated by comparing
Figure 2C and D; the former is in black and the
latter in red. No cases of b8-thalassaemia were
present in the second cohort.
iii. The detection of Hb variants. The areas of interest
were zones N1–N6 and N11, N12, N13. The N1
zone was the migration area for HbC. Thirty-three
newborns, including three premature babies,
were correctly identified as heterozygotes FAC.
The N2 zone was shared by HbA2 and HbO-Arab.
A carrier of this b-globin variant was found in a
term newborn. In the N3 zone several variants
were confirmed by IEF/HPLC: HbE in seven cases,
HbF-Ouled Rabah in one case, HbG-Philadelphia
heterozygotes in three cases. Two other samples
were assumed to contain unidentified variants.
HbF-Ouled Rabah can be differentiated from HbE
Renom et al.: Neonatal screening for SCD by Capillarys system 1429
Article in press - uncorrected proof
Figure 5 Newborns with haemoglobins D or E.
(A) F/D homozygote. (B) F/AD heterozygote: 39 w. term; 3270 g. (C) F/E homozygote: 40 w. term. (D) F/AE heterozygote: 39
w. term; 3420 g. (E) Premature F/AE heterozygote: 35 w. term; 1840 g.
Figure 6 Newborns with rare haemoglobin variants.
(A) F/AKorle-Bu heterozygote: 40 w. term; 3790 g. (B) F/AO-Arab heterozygote: 40 w. term; 3120 g. (C) FA/F-Ouled Rabah
heterozygote: 37 w. term. (D) F/AG-Philadelphia heterozygote: 39 w. term; 3490 g. (E) Fast moving foetal haemoglobin variants.
Premature baby.
on the basis of its thinner shape and intensity,
which is higher than that of HbA. Likewise, HbG-
Philadelphia can be directly identified because the
major peak in N3 was always associated with a
minor peak in N5. In the N4 zone, the main variant
was HbS: one FS homozygote and 155 FAS het-
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Figure 7 Newborns with a-thalassaemia and b-thalassaemia.
(A) Minor HbBart’s: 38 w. term; 2790 g. (B) Major HbBart’s: 39 w. term; 2400 g. (C) F/AS heterozygote with bq-thalassaemia
(S/bq-thal compound heterozygote).
erozygotes were detected and confirmed with
HPLC. Four discrepancies were observed: IEF/
HPLC results were suggestive of an a-/g-variant,
or the variant detected by IEF and Capillarys was
not revealed using HPLC. From 155 FAS profiles,
28 newborns (including 10 premature) were
screened outside the prescribed time. In the N5
zone, HbD-Punjab and HbKorle-Bu were deter-
mined and only one heterozygote of each was
found. In the N6 zone, an unidentified variant was
discovered. Its HPLC profile revealed a faint peak
in proximity to HbA. In the N11/N12 zones, we
found three fast-moving foetal Hb variants. A
minor and a major peak were found, respectively,
in N12 and N11 in two newborns. Their HPLC pro-
files showed two peaks with RTss0.22 and
0.50 min, respectively. A third variant migrated
alone in N12 (RTs0.82 min). In the N13 zone, low
amounts of Bart’s Hb were detected in 88
cases, including four associated with HbS. A very
fast-moving variant was detected in N13 which
corresponded to two peaks by HPLC (RTss0.17
and 0.25 min).
iv. The detection of altered profiles. The poor quality
of the corresponding samples did not cause false
negatives: five FAS, one FAC heterozygote and 36
with increased concentrations of HbA were cor-
rectly identified.
Fourteen profiles had a very noisy background
from N13 to N1. The common feature shared by these
samples was a period of 10–45 days between sample
collection and analysis.
Most of the profiles presenting with a noisy back-
ground were restricted to one or several migration
zones. False positives occurred most frequently
in N11 (41 cases), N13 (27 cases), N1 (15 cases),
N11qN13 (3 cases), N12qN13 (4 cases), and
N1qN11qN13 (24 cases). Among these 114 altered
profiles, 78 were performed late, between 8 and
25 days following blood collection, and 72 came from
tropical areas as Mayetta Island/Reunion Island/
French Guiana and might have been subject to rapid
ageing due to storage and travel conditions.
Reliability
The detection of the Hb variants and the automatic
labelling to sort abnormal profiles were not modified
from one run to another. The expected peaks were
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observed in the correct zones without contamination
of the other zones by unidentified material.
Discussion
The Hb genotypes from the dried blood cards used to
evaluate the Capillarys neonat fast automated sys-
tem have been determined by integrating data from
IEF and HPLC, without b-globin gene sequencing. This
means that no ‘‘confirmation’’ is provided by the com-
bination of these methods. Thus, HbS variants are
putatively identified until family studies have con-
firmed this common variant by a sickling test or
molecular analysis. In addition, patterns such as S/S,
C/C, E/E, D/D cannot be distinguished from hemiho-
mozygous syndromes with b8-thalassaemia, which is
quite important for HbE/b-thal and C/b-thal. Homozy-
gous HbE may not have clinical significance, but the
interaction of HbE with thalassaemia produces varia-
ble phenotypes ranging from mild to severe that sim-
ulate homozygous b-thalassaemia (7). Homozygous
HbC results in a compensated haemolysis (8). How-
ever, HbC/b8-thalassaemia is more severe and can
mimic b-thalassaemia intermedia (9). These draw-
backs of SCD screening using IEF and HPLC are not
resolved with CE.
In the first cohort, characteristic profiles were
obtained for preterm newborns and four cases of b8-
thalassaemia were recognised along with two cases
of bq-thalassaemia associated with HbS. The possi-
bility of detecting bq-thalassaemia or very low weight
premature infants by automatic labelling should be
possible as soon as the quantification of Hb fractions
is available. The method presented could lead to
some rare initial misinterpretations with extreme
preterm infants. The HbA peak is rather round and
not as sharp as that obtained by HPLC. However,
its differentiation from the b8-thalassaemia profile,
characterised by the presence of acetylated HbF, was
possible. Inconclusive samples that are verified by
HPLC should be genotyped. Although rare compound
heterozygous phenotypes such as HbD-Punjab, HbE,
HbO-Arab or HbG-Philadelphia interacting with HbS
were not seen in and of the newborns tested, the cor-
responding single heterozygote or homozygote con-
ditions were correctly identified by the Capillarys
neonatal fast automated system. Minor and major
HbBart’s were also detected. This technique is also
able to identify HbLepore (10). False positives found
classically by IEF (2) are not seen with CE. Samples
with HbC/HbKorle-Bu should not be misinterpreted as
heterozygous HbS/HbC. Similarly, with CE it is easy
to differentiate HbS/HbC from a HbS/HbE heterozy-
gote or a HbS carrier from HbD-Punjab, or a HbC car-
rier from a HbE carrier. Also, HbC and HbO-Arab are
clearly separated by the Capillarys, whereas these
two variants are not discriminated using IEF. In addi-
tion, rare a-globin or g-globin variants give clear pro-
files that are easily identified.
With the second cohort, we tested 6766 specimens
with the Capillarys automated system. The first
major point that we clarified is that three series of 192
samples can be analysed per day. The purchase of
two Capillarys neonat fast automated system was
optimal for performing screening for SCD in 100 000
newborns per year. If we compare CE to IEF/HPLC, an
efficient technician could analyse a maximum of 720
samples per day by IEF. However, the technician had
no ‘‘free time’’ and was fatigued. The use of a Bio-
Rad Variant Newborn Screening System with three
HPLC modules had been recommended by this com-
pany for automation of our SCD screening program
(personal communication).
The second major point was evaluation of the effi-
ciency of automated discrimination of normal profiles
from abnormal profiles. No marked discrepancy was
seen between this system and IEF. All newborns pre-
senting with SCD were identified. The percentage of
automatically selected profiles is acceptable for the
first step of SCD screening, and is no higher than the
percentage of abnormal profiles shown by IEF. Inter-
ferences from Hb variants that migrate similar to HbS
and HbC are relatively rare. Only very fast-moving
foetal Hb variants may be confused with HbBart’s.
In addition, late screening of premature babies and
screening performed using Guthrie cards of poor
quality did not markedly interfere with reporting of
the correct phenotype. However, some pitfalls can
occur. No identification of migration zones was the
most common issue. This occurs when analysis is
performed very late using Guthrie cards that are elut-
ed with more difficulty. However, this threshold is
sometimes too high since HbF can occasionally be
confused with HbA. In these cases, HbA/HbF may be
misinterpreted as HbF/HbS. The possibility of such
false positives needs to be known, and the time
between birth and analysis by CE must be taken into
consideration during validation of abnormal profiles.
This study explores a stepwise strategy for neonatal
screening of SCD. It combines the Capillarys neonat
fast automated system with second tier-testing by
HPLC. This strategy maintains the same specificity
and sensitivity as IEF/HPLC, but offers high through-
put and the advantages of more efficient automation
of the first step, full traceability, and help with inter-
pretation (automatic discrimination of abnormal sam-
ples, detection of HbBart’s, an on board library of
variants). In addition, quantitation will be soon avail-
able with ratio calculations between HbA and any
abnormal fractions. This will help the biologist to
make the diagnosis of b-thalassaemia.
Detailed description of the different
haemoglobin variantes cited in the text
HbF, foetal haemoglobin composed of a- and g-chains
(a2g2); HbA, adult haemoglobin composed of a- and b-
chains (a2b2); HbA2: minor adult haemoglobin composed of
a- and d-chains (a2d2); HbS, variant S of the b-chain (a2bS2);
HbC, variant C of the b-chain (a2bC2); HbD-Punjab, variant D-
Punjab of the b-chain (a2bD-Punjab2); HbE, variant E of the b-
chain (a2bE2); HbO-Arab (not Hbo), variant O-Arab of the
b-chain (a2bO-Arab2); HbKorle-Bu, variant Korle-Bu of the b-
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chain (a2bKorle-Bu2); HbLepore, haemoglobin composed of 2
normal a-chains and 2 d-b-fusion chain; HbG-Philadelphia,
varient G-Philadelphia of the a-chain; HbF-Ouled Rabah, var-
iant Ouled Rabah of the g-chain; g variants, variants of the
g-chain; a variants: variant of the a-chain; FS, newborn
homozygote for the variant S of adult haemoglobin; FAS,
newborn heterozygote for the variant S of the adult hae-
moglobin; FAC, newborn heterozygote for the variant C of
the adult haemoglobin; FSC, newborn compound hetero-
zygote for the variants S and C of the adult haemoglobin;
a-thalassaemia, no synthesis of a-chain; Hb Bart’s, Hb
composed by four g-chains (g4); b8-thalassaemia, no synthe-
sis of b-chain; bq-thalassaemia, decreased synthesis of b-
chain.
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